Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.
The combination of zidovudine (AZT) and 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro with AZT-sensitive and AZT-resistant clinical isolates and HIV-1IIIB. Synergy was determined by the median-effect principle and isobologram techniques. Cytotoxicity of the agents was not observed. Clinical trials are ongoing to define the combination's role in HIV-1 therapy.
Eron
J J
JJ
Infectious Disease Unit, Massachusetts General Hospital, Boston.
Johnson
V A
VA
Merrill
D P
DP
Chou
T C
TC
Hirsch
M S
MS
D004338:Drug Combinations; D004357:Drug Synergism; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D014779:Virus Replication / Q000187:drug effects; D016047:Zalcitabine / Q000494:pharmacology*; D015215:Zidovudine / Q000494:pharmacology*
D004338:Drug Combinations; D015215:Zidovudine; D016047:Zalcitabine